Dr. Reddy’s Laboratories Ltd ADR (RDY)

Currency in USD
12.94
-0.19(-1.45%)
Closed·
12.99+0.05(+0.39%)
·

Dr. Reddy’s Labs ADR (RDY) Earnings Dates & Reports

Latest Release
Jan 21, 2026
EPS / Forecast
14.52 / 0.16
Revenue / Forecast
87.27B / 935.29M
EPS Revisions
Last 90 days
Release Date
Period End
EPS
/Forecast
Revenue
/Forecast
EPS Surprise %
Revenue Surprise %
Reaction
03/2026--/0.126--/892.97M----Free Sign Up
12/202514.52/0.15787.27B/935.29M+9,142.52%+9,230.8%Free Sign Up
09/20250.196/0.1951.00B/983.13M+0.56%+1.72%Free Sign Up
06/20250.197/0.210988.91M/1.02B-6.19%-3.05%Free Sign Up
03/20250.220/0.210996.00M/961.31M+4.76%+3.61%Free Sign Up
12/20240.197/0.210969.62M/950.54M-6.43%+2.01%Free Sign Up
09/20240.178/0.206951.11M/918.01M-13.57%+3.61%Free Sign Up
06/20241.00/0.950921.00M/874.08M+5.26%+5.37%Free Sign Up
03/20240.188/0.190848.07M/848.07M-1.26%0%Free Sign Up
12/20230.990/0.890867.00M/833.44M+11.24%+4.03%Free Sign Up

All numbers in USD

Dr. Reddy’s Laboratories Ltd ADR Earnings Call Summary for Q3/2026

  • Dr. Reddy's Q3 FY26 revenue reached $971 million, exceeding forecasts by 3.8% with 4.4% YoY growth, despite stock dipping 1.47% in premarket trading
  • Strong performance in emerging markets (+32%) and India (+19%) offset North American generic business decline of 16% YoY, maintaining 53.6% gross profit margin
  • Strategic product pipeline includes Semaglutide launch in India by March 21 and in Canada between February-May, with R&D spend projected at 7-8%
  • CEO Erez Israeli highlighted double-digit growth in base business while preparing for 'very competitive markets'; company maintains $342 million net cash surplus
  • Challenges include delayed US Rituximab launch and competitive pressures, though management projects double-digit growth across most markets
Last Updated: 01/21/2026, 10:23 AM
Read Full Transcript
Dr. Reddy’s Labs ADR investor slides for Q3/2026
Dr. Reddy's Q3 FY26 slides
Last Update: Jan 21, 2026
See full investor slides

FAQ

What Is Dr. Reddy’s Labs ADR's Earnings Per Share (TTM)?

The Dr. Reddy’s Labs ADR EPS (TTM) is 67.93.

When Is The Next Dr. Reddy’s Labs ADR Earnings Date?

Dr. Reddy’s Labs ADR will release its next earnings report on May 12, 2026.

What Is Dr. Reddy’s Labs ADR’s Revenue Forecasts For Upcoming Quarters?

Dr. Reddy’s Labs ADR’s revenue forecast is 892.97M.

How Did Dr. Reddy’s Labs ADR React to the Company's Latest Earnings Report?

Dr. Reddy’s Labs ADR reported a +9,142.52% EPS surprise and a +9,230.8% revenue surprise, comparing the latest report against analyst forecasts. The stock price changed by 5.95%, reflecting the market's response to the earnings results.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.